Top news of the week: 20.09.2022.
Third Harmonic boosts biotech with sector’s top IPO in four months
The startup’s $185 million initial public offering is the largest for the sector since early May and potentially a sign of renewed investor interest in young biotechs.
Biotechnology Gets $2 Billion Boost from the White House
This week, the White House launched a watershed biotechnology and biomanufacturing initiative which has been a decade in the making.
Are Biotech IPOs Coming Back? Some Investors Think So
After a mostly lackluster year, some biotech investors see signs of revival in the solid Third Harmonic Bio public offering last week, acquisitions by big drug firms and compelling clinical ...
Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred
Is online prescribing a good idea? When is $2 billion not a lot of money? And what's going to happen at J.P. Morgan 2023? All that and more on "The Readout LOUD" #podcast this week. Listen ...
Vesalius Therapeutics, a buzzy, Flagship-backed startup, cuts jobs six months after public launch
When the company debuted in March, it announced plans to hire 200 employees over two years. Now, it’s laid off nearly half its staff in a year when the biotech sector has experienced a ...
Lessons Learned on Preparing to Weather the Inevitable Challenges in Biotech
By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC By all accounts, 2022 did not start according to plan for the biotech industry. The U.S. ...
Why a top Roche scientist is leaving after 25 years to join a rising biotech startup using fungi to make new drugs
Martin Stahl will start at LifeMine next month to lead its science unit after more than two decades as a drug hunter at the Swiss pharma giant Roche.
Back-to-back gene therapy approvals give Bluebird shot at survival
The FDA's clearances of Zynteglo and Skysona are a boost to Bluebird, and could help lift the research field after a series of setbacks. But selling the high-priced therapies will be a ...